# ORIC Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oric-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.oricpharma.com/
- Total disclosed funding: $173M
- Latest round: Series D (Aug 8, 2019)
- Investors on record: 17

## About

Founded in 2014 and based in California, US, ORIC Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was founded by Richard Heyman, Charles Sawyers, and Scott Lowe. In January 2024, ORIC Pharmaceuticals, Inc. raised USD 125 million in PIPE funding from Viking Global Investors, New Enterprise Associates, and Commodore Capital. As of 2024, the company is led by its CEO, Jacob Chacko.

ORIC Pharmaceuticals develops therapies to address cancer resistance. The firm’s pipeline project includes ORIC-114, an orally bioavailable inhibitor targeting EGFR and HER2 mutations, including those found in brain metastases; ORIC-944, a drug targeting a protein complex (PRC2) involved in several cancers, including prostate cancer; and ORIC-533, an inhibitor of CD73, an enzyme that suppresses the immune system's ability to attack cancer cells.

The company plans to use the funds raised in January 2024 to support the advancement of its clinical-stage product candidates.

## Funding rounds

- Series D, Aug 8, 2019, $55M — KKR, OrbiMed Advisors, The Column Group, Topspin Partners, Invus [DUP], Fidelity Investments, ArrowMark Partners, Foresite Capital, Casdin Capital, City Hill Ventures, Memorial Sloan-Kettering Cancer Center Pension Plan, EcoR1 Capital, Taiho Ventures, Hartford HealthCare Corporation, Irving Investors
- Series C, Feb 5, 2018, $50M — KKR, OrbiMed Advisors, Topspin Partners, Fidelity Investments, Foresite Capital, Memorial Sloan-Kettering Cancer Center Pension Plan, EcoR1 Capital, Taiho Ventures, Timefolio Capital, Trinitas Capital
- Series B, Nov 5, 2015, $53M — KKR, OrbiMed Advisors, The Column Group, Topspin Partners, Foresite Capital, EcoR1 Capital
- Series A, Dec 1, 2014, $15M — The Column Group

## Investors

- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series D
- KKR (https://capitalatlas.ai/funds/kkr) — Series B, Series C, Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C, Series D
- Topspin Partners (https://capitalatlas.ai/funds/topspin-partners) — Series B, Series C, Series D
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series B, Series C, Series D
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B, Series C, Series D
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C, Series D
- Memorial Sloan-Kettering Cancer Center Pension Plan — Series C, Series D
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series C, Series D
- Timefolio Capital — Series C
- Trinitas Capital (https://capitalatlas.ai/funds/trinitas-capital) — Series C
- Invus [DUP] — Series D
- ArrowMark Partners — Series D
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series D
- City Hill Ventures (https://capitalatlas.ai/funds/city-hill-ventures) — Series D
- Hartford HealthCare Corporation — Series D
- Irving Investors (https://capitalatlas.ai/funds/irving-investors) — Series D